Microsoft is rolling out a fix for an issue that took down Microsoft 365 services but Outlook is still experience delays.
Outlook Therapeutics will resubmit a biologics license application for its ophthalmic formulation of bevacizumab early next year after the second of two clinical trials missed a key target. The ...
Here's what investors need to know about global growth, market risks, and stock valuations before 2025, according to Goldman ...
Outlook for Mobile (which includes Outlook for Android and iOS) will make it easier for users to compose emails by allowing ...
Arista Networks' valuation appears high, but future AI growth could justify current prices for long-term investors. See why ...
Nintendo has been fairly tight-lipped about the Nintendo Switch sequel outside of confirming that 1) the console is coming ...